Global pharmaceutical leader Lupin Limited announced its strategic move to incorporate Honeywell’s Solstice® Air (HFO-1234ze(E) cGMP) as a next-generation propellant in its respiratory inhalers. This innovation is aimed at enhancing treatment options for asthma and chronic obstructive pulmonary disease (COPD), while significantly reducing the environmental impact of pressurized metered-dose inhalers (pMDIs).
Introducing a Low-Emission Alternative to Traditional Propellants
Solstice Air, developed by Honeywell, offers a groundbreaking alternative to traditional hydrofluorocarbon (HFC)-based propellants. Notably, it reduces greenhouse gas emissions by up to 99.9% compared to current options. As a non-flammable and environmentally safer solution, it enables pharmaceutical companies to meet the dual objective of ensuring patient safety and addressing climate change.
Lupin Becomes India’s First to Adopt Solstice Air at Scale
With this initiative, Lupin is set to become the first pharmaceutical company in India to adopt Solstice Air at scale in its pMDIs. By doing so, the company demonstrates its commitment to both innovation in healthcare and environmental stewardship. Lupin’s research and development efforts will focus on optimizing the use of this propellant to deliver effective therapies with a reduced carbon footprint.
Leadership Speaks on the Collaboration
Vinita Gupta, CEO of Lupin, emphasized the importance of this partnership:
“Lupin’s collaboration with Honeywell reinforces our mission to deliver high-quality, accessible medicines while prioritizing environmental responsibility. By integrating Solstice Air into our respiratory products, we are improving patient care and drastically cutting down harmful emissions.”
Ashish Modi, President of Honeywell India, echoed this sentiment:
“Solstice Air has the potential to revolutionize respiratory care by offering safe, effective treatment options that also minimize environmental damage. Our partnership with Lupin showcases how advanced technologies can drive both health innovation and sustainability.”
A Step Toward a Greener Future in Healthcare
As per the press release, through this collaboration, Lupin and Honeywell are setting a new benchmark for the pharmaceutical industry. Together, they aim to reshape the future of respiratory medicine—delivering life-saving treatments while contributing to global climate goals.